Repositioning Candidate Details
| Candidate ID: | R0472 |
| Source ID: | DB08826 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Deferiprone |
| Synonyms: | |
| Molecular Formula: | C7H9NO2 |
| SMILES: | CN1C=CC(=O)C(O)=C1C |
| Structure: |
|
| DrugBank Description: | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011. |
| CAS Number: | 30652-11-0 |
| Molecular Weight: | 139.1519 |
| DrugBank Indication: | Deferiprone is indicated in thalassemia syndromes when first line chelation agents are not adequate to treat transfusional iron overload. |
| DrugBank Pharmacology: | |
| DrugBank MoA: | Deferiprone is an iron chelator that binds to ferric ions (iron III) and forms a 3:1 (deferiprone:iron) stable complex and is then eliminated in the urine. Deferiprone is more selective for iron in which other metals such as zinc, copper, and aluminum have a lower affinity for deferiprone. |
| Targets: | Iron |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|